Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life ...

Pichia pastoris has emerged as a leading eukaryotic host for recombinant protein production, owing to its ability to perform complex post-translational modifications and grow to high cell densities ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

As key molecules on the surface of immune cells, Fc receptors are the core hub of antibody-mediated effector functions. They play an irreplaceable role in physiological processes such as ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

KACTUS, a biotechnology company located in Waltham, Massachusetts, has made commercially available ultra-low endotoxin recombinant human kallikrein-1 (KLK1) ...

Tsukuba, Japan—Recombinant protein production for pharmaceuticals and other applications often involves infecting plants with bacteria carrying specific genes to accumulate desired proteins in plants.

Escherichia coli remains at the forefront of recombinant protein production, owing to its rapid growth, well-characterised genetics and the ease with which it can be genetically manipulated. The ...

Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...

Stay up to date on the latest science with Brush Up Summaries. Finally, although transgenic animals and mammalian cell culture systems promote optimal expression due to correct protein modifications, ...

Pharming uses living organisms as bioreactors for cheaper, sustainable drug production, but requires navigating complex IP and regulatory landscapes.

Our animal-origin free recombinant proteins and enzymes portfolio, developed with Dyadic, augments Fermbox’s strategy ...